Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Bloomberg Reported Late Monday Amazon’s New Chip Moves AWS Into High-Performance Computing

News
Tech

Bloomberg Reported Late Monday Amazon’s New Chip Moves AWS Into High-Performance Computing

https://www.bloomberg.com/news/articles/2022-11-29/amazon-s-new-chip-moves-aws-into-high-performance-computing

byCharles Gross

November 29, 2022

1 minute read

https://www.bloomberg.com/news/articles/2022-11-29/amazon-s-new-chip-moves-aws-into-high-performance-computing

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report

By Vandana Singh

September 14, 7:58 AM

Bayer AG (OTC:BAYRY) has started a hunt for CEO Werner Baumann’s successor, Bloomberg News reported, citing people close to the…

BAYRY

News

Casey’s Expands Alternative Fuel Options To Further Sustainability Initiatives And Meet Guest Needs

By Benzinga Newsdesk

November 1, 9:04 AM

Casey's has doubled the number of stores with EV chargers the past year and is a leading retailer of biofuels in its footprint Casey's General Stores, Inc. (NASDAQ:CASY) continues to expand its alternative fuel

CASY

A Look Into Williams Companies Inc’s Price Over Earnings

By Benzinga Insights

July 21, 1:45 PM

In the current session, the stock is trading at $33.87, after a 0.80% spike. Over the past month,…

WMB

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7

By Benzinga Newsdesk

September 9, 8:36 AM

Morgan Stanley analyst Matthew Harrison maintains Adagene (NASDAQ:ADAG) with a Overweight and lowers the price target from $15 to $7.

ADAG

Bloomberg Reported Late Monday Amazon’s New Chip Moves AWS Into High-Performance Computing

Related Posts

After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report

Casey’s Expands Alternative Fuel Options To Further Sustainability Initiatives And Meet Guest Needs

A Look Into Williams Companies Inc’s Price Over Earnings

Morgan Stanley Maintains Overweight on Adagene, Lowers Price Target to $7